D-Pharm Appoints Dr. Brian Morgan to Board of Directors.REHOVOT, Israel--(BW HealthWire)--Nov. 26, 1999-- D-Pharm Ltd. announced today that Dr. Brian Morgan has been appointed to the company's board of directors as a non-executive board member. Dr. Morgan, a former Chairman of the Society for Medicines Research, was Director and Vice President, Scientific Licensing, Worldwide Business Development, at SmithKline Beecham until 1997. He currently serves as an independent consultant and non-executive director to a number of companies in the UK, Japan, USA and Australia. D-Pharm (www.dpharm.com) is a biopharmaceutical company applying innovative re-engineering technologies to the development of new drugs. These include newly discovered compounds and improved, patent-protected derivatives of existing drugs for the treatment of neurological disorders, cerebrovascular diseases, inflammation, cancer and AIDS. The company's most advanced product is DP-VPA, which recently completed Phase I and is slated to enter Phase II in Q1 2000. DP-VPA is a safer and more effective chemical derivative of valproic acid valproic acid /val·pro·ic ac·id/ (-ik) an anticonvulsant used particularly for the control of absence seizures. val·pro·ic acid n. An anticonvulsive drug used to treat seizure disorders. (VPA VPA Valproate VPA Vancouver Port Authority (Canada) VPA Virtual Population Analysis VPA Voluntary Partnership Agreement VPA Voluntary Placement Agreement VPA Volume Purchase Agreement VPA Vermont Principals' Association ), currently used for the treatment of epilepsy, bipolar disorder bipolar disorder, formerly manic-depressive disorder or manic-depression, severe mental disorder involving manic episodes that are usually accompanied by episodes of depression. and migraine prophylaxis. Another novel compound in D-Pharm's pipeline is DP-b99, a neuroprotective drug based on modulation of cellular divalent divalent /di·va·lent/ (di-va´lent) bivalent; carrying a valence of two. di·va·lent adj. Bivalent. di·va ion homeostasis homeostasis Any self-regulating process by which a biological or mechanical system maintains stability while adjusting to changing conditions. Systems in dynamic equilibrium reach a balance in which internal change continuously compensates for external change in a feedback . DP-b99 is slated to enter Phase I clinical studies in Q1 2000. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion